Cytek Biosciences (NASDAQ:CTKB) Posts Quarterly Earnings Results, Hits Expectations

Cytek Biosciences (NASDAQ:CTKB) posted its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09), FiscalAI reports. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. The company had revenue of $48.14 million during the quarter, compared to the consensus estimate of $47.31 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q2 revenue increased 6% year over year to $48.1 million, driven by 18% growth in the U.S., strong double-digit growth in China, high-end FSP instrument sales, and continued service momentum. Management raised the low end of full-year 2026 revenue guidance to $207 million-$212 million.
• Recurring revenue continued to strengthen, with service revenue up 10% to $15.6 million and combined reagents and service revenue representing 35% of trailing-12-month revenue. Cytek expects adjusted EBITDA to improve in the second half and reach approximately breakeven for full-year 2026.
• Cytek launched the Borealis, a 60-color, seven-laser full spectral-flow cytometer, and expanded Aurora Evo automation capabilities for biopharma and CRO laboratories. Management said early customer feedback on Borealis has been strong and believes the products can support future market-share gains.
• Regional and profitability pressures persisted: EMEA revenue declined approximately 8% amid government budget constraints, while GAAP net loss widened to $12.2 million from $5.6 million a year earlier. Operating expenses rose 15%, including higher legal costs tied to patent litigation and increased personnel expenses.
• The company began reorganizing into three customer-aligned business units—Solutions and Clinical, Research Technology, and Service—aiming to improve market penetration and growth, particularly in mid- and low-end instruments, reagents, and clinical applications. Management said the benefits will take time to materialize and are already incorporated into 2026 guidance.

Cytek Biosciences Trading Down 2.3%

Shares of CTKB traded down $0.10 during mid-day trading on Wednesday, reaching $4.18. The company’s stock had a trading volume of 993,945 shares, compared to its average volume of 751,687. Cytek Biosciences has a 52 week low of $3.28 and a 52 week high of $6.18. The company’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $4.43.

Hedge Funds Weigh In On Cytek Biosciences

Large investors have recently added to or reduced their stakes in the business. Topline Capital Management LLC boosted its position in Cytek Biosciences by 255.7% during the second quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock valued at $17,786,000 after buying an additional 3,760,485 shares during the period. Boston Partners grew its stake in shares of Cytek Biosciences by 13,369.4% during the fourth quarter. Boston Partners now owns 5,008,309 shares of the company’s stock valued at $25,297,000 after buying an additional 4,971,126 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Cytek Biosciences by 39.0% in the fourth quarter. Millennium Management LLC now owns 4,752,447 shares of the company’s stock worth $24,000,000 after buying an additional 1,334,065 shares during the period. State Street Corp increased its holdings in shares of Cytek Biosciences by 1.5% in the fourth quarter. State Street Corp now owns 4,146,964 shares of the company’s stock worth $20,942,000 after buying an additional 62,596 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Cytek Biosciences by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 2,790,574 shares of the company’s stock valued at $14,096,000 after acquiring an additional 7,125 shares during the last quarter. Hedge funds and other institutional investors own 69.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CTKB. Morgan Stanley reduced their target price on Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a research note on Wednesday, June 24th. Finally, Stephens cut their price objective on Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.69.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.